Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: J Immunol. 2013 May 1;190(11):5818–5828. doi: 10.4049/jimmunol.1203452

Figure 1.

Figure 1

DNMAML inhibits graft-versus-host disease mediated by CD4+ and/or CD8+ T cells after MHC-mismatched bone marrow transplantation. Lethally irradiated BALB/c mice (H-2d) were transplanted with B6 T cell-depleted bone marrow (TCD BM, 5×106 cells) alone or with (A) B6 (H-2b) splenocytes containing CD4+ and CD8+ T cells from wild-type (WT) or DNMAML mice (10×106 cells; 16 mice/group) (p<0.001 for WT vs. TCD and WT vs. DNMAML survival); (B) purified B6 WT or DNMAML CD4+ T cells (2×106 cells; 8–17 mice/group) (pp<0.001 for WT vs. TCD and WT vs. DNMAML survival); (C) purified B6 WT or DNMAML CD8+ T cells (5×106 cells; 13–17 mice/group) (p<0.01 for WT vs. TCD; p<0.001 for WT vs. DNMAML survival). Recipients were monitored over time for survival and GVHD severity after transplantation (clinical GVHD score, 0–10).